Daewoong wins permission for Nabota in Argentina
South Korea's Daewoong Pharmaceutical Co. announced on Monday that its botulinum toxin Nabota received product approval from Argentina's National Ad...
PharmaResearch acquires TuringBio for digital therapeutics
PharmaResearch Co., a South Korean company specializing in regenerative medicine, announced on Wednesday that it acquired TuringBio, an AI-based dig...
Daewoong, Indonesia's IPB to co-research on primate
South Korea's Daewoong Pharmaceutical Co. announced on Thursday that it signed a contract with Indonesia's Bogor Agricultural University (Institut P...
Korean biotech Xcell Therapeutics eyes June IPO
South Korean biotech Xcell Therapeutics Inc., a developer of chemically defined media for in vitro cell culture, is aiming for a junior bourse Kosda...
Samsung invests in BrickBio in US
Samsung Group announced on Tuesday that its Life Science Fund has invested in the US-based antibody-drug conjugates (ADC) and gene therapy technol...
Daewoong Pharmaceutical digitizes DB of 800 mn chemical compounds
South Korea's Daewoong Pharmaceutical announced on Monday that it has established a drug development system Daewoong AI System (DAISY) which combine...
Daewoong gets stem cell facility license in Indonesia
South Korea's Daewoong Pharmaceutical announced on Tuesday that its subsidiary Daewoong Biologics Indonesia has obtained a stem cell Lab Operational...
Daewoong exports $92.4 mn Depot injection tech to UAE
South Korea's Daewoong Pharmaceutical announced on Monday that it exported its technology for clinical development and commercialization rights of i...
Daewoong Pharm set to export Envlo Tab to Russia, CIS
Daewoong Pharmaceutical, a leading South Korean pharmaceutical company will export its new diabetes drug Envlo Tab. (active ingredient:enavogliflozi...
Daewoong Pharma, Merck team up for AI tech for new drug
South Korea's Daewoong Pharmaceutical announced on Tuesday it signed with memorandum of understanding (MOU) with Merck Life Science to build an arti...
Daewoong Pharma's GER drug gets product OK from Mexico
South Korea’s Daewoong Pharmaceutical on Wednesday said its gastroesophageal reflux (GER) disease drug Fexuclue (active ingredient fexuprazan ...
Daewoong to develop eye drops for diabetic retinopathy
South Korea's Daewoong Pharmaceutical is venturing into the development of a product that can easily treat diabetic retinopathy in the form of ...
Daewoong gets patent of Nabota as migraine drug in US
South Korea's Daewoong Pharmaceutical Co. announced on Thursday that it has received a patent from the US Patent and Trademark Office for the use of...
Daewoong applies for approval of Envlo in Saudi Arabia
South Korea's Daewoong Pharmaceutical Co. announced on Friday that it has submitted an application for regulatory approval of its new diabetes treat...
Daewoong launches GERD treatment Fexuclu in Philippines
South Korea's Daewoong Pharmaceutical announced on Tuesday that it has launched the GERD treatment drug "Fexuclue" (active ingredient: Fexuprazan) i...
Daewoong's Nabota exceeds 600,000 customers in US
South Korea's Daewoong Pharmaceutical said on Thursday that its local loyalty program for Nabota (American name: Jeuveau) in the US, a botulinum tox...
Celltrion to develop Humira biosimilar oral medication with US firm
South Korea's biopharmaceutical company Celltrion Inc. announced on Monday that it has signed a contract with the US biotech firm Rani Therapeutics ...
HanAll, Daewoong to develop Parkinson's treatment with US partner
South Korea's HanAll Biopharma Co. and Daewoong Pharmaceutical on Thursday said they concluded a contract with NurrOn Pharmaceuticals of the US on...
Daewoong Pharmaceutical’s cumulative tech exports exceed $870 mn
South Korea’s Daewoong Pharmaceutical said on Friday that it had concluded three technology export agreements for new drugs and new drug candi...
Daewoong Pharma to build third botulinum toxin plant for $746 mn
South Korea’s Daewoong Pharmaceutical next year will open a third plant to greatly expand annual output of its botulinum toxin Nabota at a cos...
Daewoong to transfer techs for autoimmune disease to US pharma
South Korea's Daewoong Pharmaceutical announced on Friday that it has signed a technology export contract for the clinical development and commercia...
Welt gets second digital therapeutic device approval in S. Korea
South Korea's Ministry of Food and Drug Safety announced on Wednesday that it has approved the cognitive therapy software "WELT-I" developed by We...
Daewoong Pharma, UK firm to jointly develop autoimmune disease drug
South Korean drugmaker Daewoong Pharmaceutical Co. said on Tuesday that it has signed a cooperation agreement with Sygnature Discovery, a British ne...
Vaxcell-bio's NK cell therapy wins therapeutic approval for liver cancer
South Korean anti-cancer immunotherapy company Vaxcell-Bio Therapeutics announced on Friday that its natural killer (NK) cell therapy, Vax-NK/HCC, h...
Daewoong wins approval for GERD treatment Fexuclu in Chile
South Korean pharmaceutical company Daewoong Pharmaceutical announced on Tuesday that it has received marketing authorization from Chile's National ...
GC Biopharma to develop mRNA flu vaccine with Canadian pharma
South Korea's GC Biopharma Corp. announced on Thursday that it will start developing a flu vaccine based on messenger ribonucleic acid (mRNA).The dr...
Daewoong’s Nabota expands into Germany, Austria
South Korean drugmaker Daewoong Pharmaceutical Co. said on Tuesday it had launched its botulinum toxin product Nabota in Germany and Austria through i...
Daewoong Pharma's Fexuclue safe to use with aspirin: Clinical trials
Daewoong Pharmaceutical Co., a leading South Korean pharmaceutical company, has announced the successful completion of phase 1 clinical trials for...
Korea's Daewoong to export diabetes drug Envlo to Brazil, Mexico
South Korea’s Daewoong Pharmaceutical Co. said on Feb. 24 it is set to embark on global sales of Envlo, a new drug for diabetes, by exportin...
AIMMED’s Somzz ushers in digital therapeutic device market in Korea
South Korea’s health and drug safety authority has cleared Somzz to treat patients with sleep disorders, a dynamic move that is expected to vi...
